Table 2 Clinical data on DEB-TACE

Median dose of oxaliplatin, mg

105.1±15.4

Lobaplatin, mg

20.9±3.0

Polyvinyl alcohol particles

3 (12.0%)4

Gelatin sponge particles

8 (32.0%)11

Embolization microspheres

2 (8.0%)

Median inpatient duration, months

9.0 (7.0, 13.3)

Mean cost of hospitalization, ×10⁴ RMB

5.3±1.4

Mean session of DEB-TACE

1.8±1.4

Mean procedure time, min

73.7±24.7

Complications, n (%)

13 (52.0%)

 Fever

3 (12.0%)

 Nausea and/or vomiting

7 (28.0%)

 Abdominal pain

9 (36.0%)

 Cardiotoxicity

1 (4.0%)

Other treatments, n (%)

10 (40.0%)

 Thermal ablation

9 (36.0%)

 ¹²⁵I seeds implantation

3 (12.0%)